It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the processes responsible for these observations are incompletely understood. Here we use high-throughput, single-genome amplification and sequencing (HT-SGS) to sequence SARS-CoV-2 spike genes from people with HIV (PWH, n = 22) and people without HIV (PWOH, n = 25). In PWOH and PWH with CD4 T cell counts (i.e., CD4 counts) ≥ 200 cells/μL, we find that most SARS-CoV-2 genomes sampled in each person share one spike sequence. By contrast, in people with advanced HIV infection (i.e., CD4 counts < 200 cells/μL), HT-SGS reveals a median of 46 distinct linked groupings of spike mutations per person. Elevated intra-host spike diversity in people with advanced HIV infection is detected immediately after COVID-19 symptom onset, and early intra-host spike diversity predicts SARS-CoV-2 shedding duration among PWH. Analysis of longitudinal timepoints reveals rapid fluctuations in spike sequence populations, replacement of founder sequences by groups of new haplotypes, and positive selection at functionally important residues. These findings demonstrate remarkable intra-host genetic diversity of SARS-CoV-2 in advanced HIV infection and suggest that adaptive intra-host SARS-CoV-2 evolution in this setting may contribute to the emergence of new variants of concern.
High-throughput, single-copy sequencing of SARS-CoV-2 spike in a longitudinal cohort of people with and without HIV infection demonstrates striking intra-host diversity and adaptive evolution of SARS-CoV-2 in people with advanced HIV infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 National Institutes of Health, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.94365.3d) (ISNI:0000 0004 0630 4646); University of the Witwatersrand, SAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135)
3 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 0630 4646)
4 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 0630 4646); University of the Witwatersrand, School of Public Health, Faculty of Health Sciences, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135)
5 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 0630 4646); University of Guelph, Department of Integrative Biology and Bioinformatics, College of Biological Sciences, Ontario, Canada (GRID:grid.34429.38) (ISNI:0000 0004 1936 8198)
6 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.94365.3d) (ISNI:0000 0004 0630 4646)
7 University of the Witwatersrand, Perinatal HIV Research Unit, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135); Center for TB Research, Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
8 University of the Witwatersrand, Perinatal HIV Research Unit, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135)
9 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.94365.3d) (ISNI:0000 0004 0630 4646); University of the Witwatersrand, School of Pathology, Faculty of Health Sciences, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135)
10 a division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 0630 4646); University of the Witwatersrand, School of Pathology, Faculty of Health Sciences, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135)